

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
LigoChem, Inc.	05/30/2003
RECEIVING PARTY DATA	
Name:	Mr. Barry Forman
Street Address:	300 Maiden Lane East
City:	Seattle
State/Country:	WASHINGTON
Postal Code:	98112
PROPERTY NUMBERS Total: 5	
Property Type	Number
Patent Number:	5294681
Patent Number:	5658779
Patent Number:	5770712
Patent Number:	5885921
Patent Number:	5534597
CORRESPONDENCE DATA	
Fax Number:	(973)597-2400
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	973-597-2500
Email:	lstrademark@lowenstein.com
Correspondent Name:	Nicholas G. Mehler, Esq.
Address Line 1:	Lowenstein Sandler PC
Address Line 2:	65 Livingston Avenue
Address Line 4:	Roseland, NEW JERSEY 07068-1791
NAME OF SUBMITTER:	Nicholas G. Mehler, Esq.

CH \$200.00 5294681

Total Attachments: 4

source=Ligochem, Inc. (Patent Assignment to B. Forman)#page1.tif

source=Ligochem, Inc. (Patent Assignment to B. Forman)#page2.tif

source=Ligochem, Inc. (Patent Assignment to B. Forman)#page3.tif

source=Ligochem, Inc. (Patent Assignment to B. Forman)#page4.tif

new dimensions in

bio  *separations*

LigoChem, Inc.
130 Fairfield Road
Fairfield, NJ 07004

May 30, 2003

Barry Forman
300 Maiden Lane East
Seattle, WA 98112

Dear Mr. Forman;


LigoChem, Inc. and its parent company, LigoTech, Inc. (hereinafter, "LIGO") hereby acknowledge receipt of your letter dated April 28, 2003 in which you, as THE SECURED PARTY, demand immediate payment of all principal and unpaid interest due respecting the Secured Promissory Note executed by LigoTech, Inc. and LigoChem, Inc. on May 18, 1998, (hereinafter, the "NOTE"). Your letter and the parts of the NOTE are attached to this letter for reference.

LIGO further acknowledges that it is in breach of the terms of the NOTE by having failed to repay the principal and all outstanding interest upon the NOTE by the Maturity Date named therein, that being June 1, 2001.

LIGO further affirms that it cannot now meet the demand for payment, nor does it expect to be able to do so in the foreseeable future.

LIGO further affirms that it intends in the near future to liquidate, either in bankruptcy, or by other means, the entities of which LIGO is comprised.

LIGO further affirms that, preparatory to such liquidation, it has ceased normal operations, having closed its laboratory and sold certain equipment in order to honor its lease and to help fund a bankruptcy exercise.



PATENT

REEL: 016245 FRAME: 0889

new dimensions in

bio  *separations*

LIGO therefore acknowledges that, by virtue of the above affirmations which constitute default on the NOTE by LIGO, does THE SECURED PARTY have the right to seek remedies as set forth under Section 9 REMEDIES of the Security Agreement and Assignment dated 5.18.1998 respecting the NOTE.

The assets which secure the NOTE and which are transferrable to THE SECURED PARTY are enumerated in general terms in Section 1 Assignment and Grant of Security of the Security Agreement and Assignment dated 5.18.1998 respecting the NOTE.

LIGO as Obligor, in accord with its duties as the named DEBTOR in the NOTE, hereby assents to the transmittal of all assets due THE SECURED PARTY including, but not limited to all rights in the proprietary intellectual property and the products of LIGO. BY VIRTUE OF THIS LETTER, LIGO HEREBY ASSIGNS AND CONVEYS THESE RIGHTS AS OF THE DATE OF THIS LETTER. THESE PARTICULAR RIGHTS EXIST SEPARATE FROM, INDEPENDENT AND OUTSIDE OF ANY POSSESSION OF CERTIFIED US OFFICE PATENT AND TRADEMARK DOCUMENTS describing the inventions which form the basis of these rights.

Regarding cure of the default on this NOTE, certain of these assets are readily available and can be transmitted at once, those being rights to the existing proprietary intellectual property and demonstration thereto by relevant certified patents, Standard Operating Procedures in the manufacture and use of the products which constitutes unprotected secret lore, other unprotected lore and expertise, product literature, the sales manual, presentation material, the customer list and certain chattel in paper and electronic form. Other items can be transmitted at or near to the closure of the company, among them but not limited to; receivables accounts, proceeds from the sale of office equipment, bank balances, existing contracts.



PATENT

REEL: 016245 FRAME: 0890

new dimensions in

bio  *separations*

Furthermore, LIGO affirms that ~~THE SECURED PARTY shall be due interest~~
upon the NOTE as of the date of the completed conveyance of all assets due him
respecting the NOTE


LIGO has begun the process of transmittal by furnishing the above immediately
accessible assets and will keep THE SECURED PARTY apprised of its
compliance in this matter. A list of assets will be separately furnished and their
disposition by transmittal to THE SECURED PARTY shall be noted and
confirmed by both sides.

LIGO acknowledges that THE SECURED PARTY is due all receipts as of this
letter but requests that these receipts be used to keep the office open to
complete the liquidation of LIGO, the transmittal of assets and if possible to
establish product continuity after the closure of LIGO. Please comment on this
request.

Sincerely,



David Golub
President and CEO
LigoTech, Inc. and LigoChem, Inc.



PATENT
REEL: 016245 FRAME: 0891

new dimensions in

bio  *separations*

Attachment to the LigoChem, Inc. Letter to Barry Forman dated May 30, 2003

INTELLECTUAL PROPERTY transferred to Barry Forman from LigoTech, Inc. per the terms of the Security Agreement and Assignment Dated May 18, 1998 between LigoTech, Inc., LigoChem, Inc. and Barry Forman, includes but is not limited to:

I. Patents

- I.i. USP #5294681 "PBNP"
- I.ii. USP #5,658,779 "VirAffinity"
- I.iii. USP #5,770,712 "Axces"
- I.iv. USP #5,885,921 "Cleanascite"
- I.v. USP #5,534,597

Trademarks and Tradenames


- II.i. ProPrep™ and ProPrep™ Kits
 - II.i.a. ProPrep BAC
 - II.i.b. ProPrep™ Plasmid
 - II.i.c. ProPrep™ Omni
 - II.i.d. ProPrep™ Whole Blood Genomic
 - II.i.e. Proprep™ Genomic Paper
- II.ii. ProCipitate™
- II.iii. DNable™
- II.iv. Viraffinity™
- II.v. Hemoglobind™
- II.vi. Cleanascite™
- II.vii. LigoSep™ and LigoSep™ Ligands Alpha, Beta, Delta
- II.viii. LigoLinx™
- II.iv. All new products developed or evolved from the above.

II. Proprietary Lore and Expertise includes all Standard Operating Procedures (SOPs) and published and unpublished protocols for the manufacture and use of I and II above.

III. Sales Manual

IV. Customer Accounts

Attachment to the LigoChem, Inc. Letter to Barry Forman dated May 30,



PATENT